Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 20/20 | 0.38 |
| ▸ | MC5R | P33032 | 3/20 | 0.37 |
| ▸ | MC3R | P41968 | 3/20 | 0.37 |
| ▸ | MC1R | Q01726 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033856 | 0.88 | MC4R (0.41) | MC4RMC5RMC3RMC1R | |
| SCHEMBL13393509 | 0.86 | MC4R (0.38) | MC4RMC5RMC3RMC1R | |
| SCHEMBL13393614 | 0.86 | MC4R (0.40) | MC4RMC5RMC3RMC1R | |
| SCHEMBL13393510 | 0.83 | MC4R (0.41) | MC4RMC5RMC3RMC1R | |
| SCHEMBL13393609 | 0.83 | SLC2A1 (0.39) | MC4RMC5RMC3RMC1R | |
| SCHEMBL13393429 | 0.83 | MC4R (0.40) | MC4RMC5RMC3RMC1R | |
| SCHEMBL13393423 | 0.82 | MC4R (0.38) | MC4RMC5RMC3RMC1R | |
| SCHEMBL13393518 | 0.82 | MC4R (0.40) | MC4RMC5RMC3RMC1R | |
| SCHEMBL12989662 | 0.81 | MC4R (0.39) | MC4RMC5RMC3RMC1R | |
| SCHEMBL13393511 | 0.81 | MC4R (0.44) | MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010034500-A1 | SUBSTITUTED IMIDAZOPYRIDINE, IMIDAZOPYRAZINE, IMIDAZOPYRIDAZINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| EP-2168965-A1 | Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-03-31 | — | — | EP | disclosed |